Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm
Aneurysm, Cerebral, Endovascular Procedures
About this trial
This is an interventional treatment trial for Aneurysm, Cerebral focused on measuring antiplatelet preparation, cerebral aneurysm, coil embolization
Eligibility Criteria
Inclusion Criteria:
- patients with clopidogrel resistance (greater than 220 P2Y12 reaction units using VerifyNow)
- patients with unruptured intracranial aneurysms
- patients over 20 years old
- patients who can communicate with each other
- patients who agreed to this study (with informed consent)
Exclusion Criteria:
- patients with recurrent aneurysms after coiling or clipping
- patients with allergic reaction to antiplatelets
- patients with high risks of hemorrhage
- patients with coagulopathy
- patients with thrombocytopenia (<100,000/mm3)
- patients with liver disease (> 100 of aspartate aminotransferase or alanine aminotransferase)
- patients with renal disease (> 2mg/dL of serum creatinine)
- patients with uncontrolled heart failure or angina
- patients with malignant tumor
- pregnant patients
- patients with past history that may associated with headache, including subarachnoid hemorrhage, head trauma, intracerebral hemorrhage, trigeminal neuralgia, arteriovenous malformation, brain tumor)
- Patients who are determined to be disqualified by researchers
Sites / Locations
- Seoul National Univeristy Bundang Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
dual-antiplatelet
triple-antiplatelet
Patients with unruptured aneurysms received dual antiplatelet agents (100 mg of aspirin and 75 mg of clopidogrel) for at least five days before embolization. One day prior to coil embolization, P2Y12 reaction units were measured using VerifyNow. Patients with clopidogrel resistance (greater than 220 PRU) received prasugrel 20mg. After that, dual-antiplatelet (aspirin 100mg & prasugrel 5mg) treatment continued for 3 months through study completion.
Patients with unruptured aneurysms received dual antiplatelet agents (100 mg of aspirin and 75 mg of clopidogrel) for at least five days before embolization. One day prior to coil embolization, P2Y12 reaction units (PRU) were measured using VerifyNow. Patients with clopidogrel resistance (greater than 220 PRU) received cilostazol 200mg. After that, triple-antiplatelet (aspirin 100mg, clopidogrel 75mg, and cilostazol 200mg) treatment continued for 3 months through study completion.